Zymeworks (ZYME) Non-Current Assets (2021 - 2026)
Zymeworks' (ZYME) quarterly Non-Current Assets came in at $92.5 million in Q1 2026, down 22.28% year-on-year from $119.1 million in Q1 2025, and down 5.34% quarter-over-quarter from $97.8 million in Q4 2025.
Zymeworks (ZYME) Non-Current Assets (2021 - 2026) Analysis & Trends
Zymeworks has disclosed Non-Current Assets across 6 years of filings, most recently posting $92.5 million for Q1 2026.
- Non-Current Assets for Q1 2026 came in at $92.5 million, down 22.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $408.1 million (down 26.76% YoY), and the FY2025 annual result was $97.8 million, down 39.89% from the prior year.
- Non-Current Assets came in at $92.5 million for Q1 2026 at Zymeworks, down from $97.8 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $181.7 million in Q3 2023 to a low of $92.5 million in Q1 2026.
- The 5-year median for Non-Current Assets is $132.1 million (2024), against an average of $136.3 million.
- Across the five-year window, Non-Current Assets surged 65.8% in 2023 and sank 39.89% in 2025, its largest moves.
- Zymeworks' Non-Current Assets stood at $104.0 million in 2022, then jumped by 61.46% to $168.0 million in 2023, then dropped by 3.16% to $162.6 million in 2024, then tumbled by 39.89% to $97.8 million in 2025, then slipped by 5.34% to $92.5 million in 2026.
- The last three Non-Current Assets figures came in at $92.5 million (Q1 2026), $97.8 million (Q4 2025), and $105.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Zymeworks | 1.73 Bn | 1.36 Bn | - | 92.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 92.54 Mn |
| Dec 31, 2025 | 97.76 Mn |
| Sep 30, 2025 | 105.56 Mn |
| Jun 30, 2025 | 112.26 Mn |
| Mar 31, 2025 | 119.06 Mn |
| Dec 31, 2024 | 162.64 Mn |
| Sep 30, 2024 | 143.38 Mn |
| Jun 30, 2024 | 132.14 Mn |
| Mar 31, 2024 | 159.93 Mn |
| Dec 31, 2023 | 167.95 Mn |
| Sep 30, 2023 | 181.73 Mn |
| Jun 30, 2023 | 181.72 Mn |
| Mar 31, 2023 | 174.37 Mn |
| Dec 31, 2022 | 104.02 Mn |
| Sep 30, 2022 | 109.61 Mn |
| Dec 31, 2021 | 100.91 Mn |